TCM
KRYS icon

Tradewinds Capital Management’s Krystal Biotech KRYS Stock Holding History

Tradewinds Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1
Closed -$138 – 691
2025
Q2 		$138 Buy
+1
New +$147 ﹤0.01% 605

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Tradewinds Capital Management's KRYS Position: Q3 2025 in Review

Tradewinds Capital Management sold out of Krystal Biotech (KRYS) in Q3 2025, closing a stake of 1 share — an estimated $138 sold.

Tradewinds Capital Management first reported a position in KRYS in Q2 2025 and held it in 1 quarter. The position peaked at $138 in Q2 2025. 284 funds tracked by Wall St. Rank hold KRYS as of Q3 2025.

  • Tradewinds Capital Management reported no remaining Krystal Biotech position as of Q3 2025 after selling out during the quarter.
  • Tradewinds Capital Management sold 1 Krystal Biotech share in Q3 2025, an estimated $138.
  • Tradewinds Capital Management first reported a position in Krystal Biotech in Q2 2025 and held it in 1 quarter.
  • Tradewinds Capital Management's Krystal Biotech position peaked at $138 in Q2 2025.
  • 284 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2025.

Based on Tradewinds Capital Management's 13F filing for Q3 2025, filed 21 Oct 2025.